Compare NUS & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | REFI |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.4M | 255.6M |
| IPO Year | 1996 | 2021 |
| Metric | NUS | REFI |
|---|---|---|
| Price | $10.07 | $12.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 461.4K | 122.0K |
| Earning Date | 02-12-2026 | 11-04-2025 |
| Dividend Yield | 2.38% | ★ 15.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.20 | 1.69 |
| Revenue | ★ $1,560,391,000.00 | $54,287,847.00 |
| Revenue This Year | N/A | $13.78 |
| Revenue Next Year | $2.12 | $4.07 |
| P/E Ratio | ★ $4.59 | $7.62 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.32 | $11.85 |
| 52 Week High | $14.62 | $16.29 |
| Indicator | NUS | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 48.99 |
| Support Level | $9.94 | $12.66 |
| Resistance Level | $10.35 | $13.25 |
| Average True Range (ATR) | 0.31 | 0.29 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 31.88 | 25.28 |
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.